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Table 1 99th centile=the upper reference limit as determined in a healthy reference range 
population
99th centile
(Diagnostic threshold)
10% coefficient of 
variation* Limit of detection
Roche Elecsys high-
sensitivity cardiac troponin 
T2
14 ng/L 13 ng/L 5 ng/L
Abbott ARCHITECTSTAT 
high-sensitivity cardiac 
troponin I3
16 ng/L (females)
34 ng/L (males)
26 ng/L (single threshold)
4.7 ng/L 2 ng/L
Limit of detection,the lowest concentration which can be reliably distinguished from a sample with no troponin 
present.
*Lowest concentration where coefficient of variation is <10% (measure of dispersion of replicate sample results 
around the mean (SD/mean)).
A single blood test to rule out acute 
coronary syndrome
Andrew R Chapman, Nicholas L Mills
Strategies to improve the assessment of 
patients with suspected acute coronary 
syndrome continue to evolve, in recogni-
tion that fewer than 20% of those 
attending the Emergency Department 
with chest pain receive a diagnosis of 
myocardial infarction. Identifying patients 
without myocardial infarction at an earlier 
stage has the potential to reduce hospital 
admissions for serial cardiac biomarker 
testing, and facilitate appropriate investi-
gation for alternative causes. However, 
such strategies are only helpful if it can be 
demonstrated that they do not compro-
mise patient safety.
In 2016, the National Institute for 
Health and Care Excellence (NICE) 
updated their guidance on the evaluation 
of patients with suspected acute coronary 
syndrome. For the first time, they recom-
mended clinicians consider ruling out 
myocardial infarction if a patient has very 
low concentrations of cardiac troponin 
at presentation when measured using 
a high-sensitivity assay.1 This guidance 
could lead to a significant reduction in 
the proportion of patients who require 
serial testing, and may tempt clinicians to 
consider upgrading their infrastructure to 
facilitate implementation. In the UK, two 
high-sensitivity assays are recommended 
by NICE for use in clinical practice, the 
Roche Elecsys high-sensitivity cardiac 
troponin T assay (hs-cTnT) and the Abbott 
ARCHITECTSTAT high-sensitivity cardiac 
troponin I assay (hs-cTnI). These assays 
measure different subtypes of cardiac 
troponin, and there are important differ-
ences in the normal reference range, diag-
nostic thresholds, levels of imprecision 
and in the lowest absolute concentrations 
which can be reliably detected, also known 
as the limit of detection (LoD) (Table 1).
NICE recommend clinicians apply the 
LoD as a threshold below which myocar-
dial infarction can be safely ruled out 
at presentation. Such a strategy is only 
recommended for patients deemed to be 
at low risk of myocardial infarction ‘as 
indicated by a validated tool’. During 
their appraisal, NICE considered evidence 
from studies including both the Throm-
bolysis in Myocardial Infarction (TIMI) 
score and the Global Registry of Acute 
Coronary Events score. Both scores were 
derived and validated in patients with 
confirmed myocardial infarction to confer 
prognosis, but over time, these scores 
have been implemented for risk strati-
fication in patients with suspected, not 
confirmed, myocardial infarction. Impor-
tantly, cardiac troponin concentrations are 
embedded in both risk scores. NICE ulti-
mately recommend the TIMI score, which 
has been previously validated in patients 
with suspected acute coronary syndrome 
alongside a contemporary troponin assay 
and serial testing,4 but not with a high-sen-
sitivity assay and the LoD at presentation 
alone.
Carlton et al provide the first valida-
tion of the NICE guidance in a pooled 
study of over 5000 patients, in five 
observational cohorts across two conti-
nents, with varying prevalence of major 
adverse cardiovascular events (4.8% to 
15.6%).5 They found when an hs-cTnT 
of <5 ng/L (LoD) was applied alongside 
a TIMI score of 0 and a non-ischaemic 
ECG, the sensitivity and negative predic-
tive value (NPV) were extremely high, 
at 99.5% (95% CI 98.1% to 99.9%) 
and 99.6% (95% CI 98.7% to 100%), 
respectively. They derived a meta-esti-
mate for sensitivity of 98.7% (95% CI 
96.5% to 99.6%), with low heterogeneity 
observed between cohorts (I2 15.3). For 
the hs-cTnI, using the LoD (<2 ng/L) and 
a TIMI score of 0 alongside a non-isch-
aemic ECG, the sensitivity was 98.9% 
(95%CI 97.4% to 99.6%) and NPV was 
99.5% (95%CI 98.8% to 99.8%). The 
meta-estimate for sensitivity was similar 
(98.5%, 95% CI 95.4% to 99.5%) but 
the heterogeneity was high (I2 73.7). The 
reason for the observed heterogeneity is 
unclear, but may reflect differences in the 
assay used for diagnostic adjudication and 
testing between cohorts. These strategies 
would identify between 17.9% (95% CI 
16.6% to 19.3%) and 21.0% (95% CI 
19.9% to 22.2%) of patients as low risk, 
respectively. The authors evaluate several 
additional approaches not included in 
the recommendations of NICE, including 
the use of thresholds above the LoD in 
combination with the TIMI score, and 
their data suggest that higher thresholds 
(such as <7 ng/L on the hs-cTnT assay, 
or <5 ng/L on the hs-cTnI assay) could 
increase in the proportion identified as 
low risk without compromising sensitivity 
or NPV.
While NICE recommend use of the 
TIMI score, the true need for clinical risk 
scores in this setting is uncertain. A recent 
meta-analysis of 9269 patients found a 
normal ECG and an hs-cTnT result below 
the LoD provided excellent NPV (99.3%, 
95% CI 97.3% to 99.8%) and sensitivity 
(98.7%, 95% CI 96.6% to 99.5%) for 
the diagnosis of myocardial infarction, 
without the need for additional risk 
scores.6 There were no deaths at 30 days 
in patients classified as low risk with the 
index test. This reflects our understanding 
that patients classically considered high 
risk (due to increasing age or cardiovas-
cular risk factors such as diabetes, renal 
disease or prior ischaemic heart disease) 
have chronic elevation in high-sensitivity 
cardiac troponin concentrations (within 
the normal reference range) and are 
less likely to have low concentrations to 
support early discharge. Indeed, the Euro-
pean Society of Cardiology advocate use 
of the LoD at presentation in conjunction 
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Editorial
with the ECG, but do not recommend the 
addition of clinical risk scores.
However, there is undoubtedly an 
appetite for clinical risk scores in some 
settings, perhaps due to the additional 
perceived diagnostic confidence they 
provide. One of the most widely used risk 
scores, the HEART score, was developed 
and validated in a suspected acute coro-
nary syndrome population. This score is 
based on clinical variables selected a priori 
(History, ECG, Age, Risk factors, cardiac 
Troponin) with arbitrary weighting chosen 
on a pragmatic basis. A recent meta-anal-
ysis of 11 217 patients demonstrated this 
score had a sensitivity of just 96.7% (95% 
CI 94.0% to 98.2%), below the threshold 
of 99% which most emergency department 
physicians deem acceptable.7 Whether use 
of this score offers additional benefit over 
risk stratification with troponin alone is 
unclear. Comparative studies including 
risk stratification thresholds alone or in 
combination with risk scores are required 
to determine if improvements in safety 
can be obtained.
There are important limitations to the 
study findings of Carlton et al. It is notable 
that there was a significant proportion 
of missing data, with over 2000 patients 
excluded from the hs-cTnT cohort and 
784 patients from the hs-cTnI cohort. 
This reflects the pragmatic basis on which 
the data were compiled for this study, but 
may have contributed to important differ-
ences in risk profile between cohorts. 
Patients in the hs-cTnT cohort were older, 
with more cardiovascular risk factors, and 
one may therefore anticipate higher base-
line cardiac troponin concentrations and 
a reduced likelihood of a missed myocar-
dial infarction compared with the hs-cTnI 
cohort.
So, is it time to adopt the NICE guid-
ance? The evidence supporting imple-
mentation of strategies including low 
high-sensitivity cardiac troponin concen-
trations is strong, but some uncertainty 
remains. All studies on which the NICE 
recommendations are based were obser-
vational in nature (ie, no patients were 
discharged from hospital on the basis of 
a single troponin result), and the same 
applies to the vast majority of studies 
in this area. A multicentre randomised 
controlled trial of implementation of a 
rule-out strategy using a single hs-cTnI 
concentration (<5 ng/L) has completed 
recruitment in Scotland (NCT:03005158), 
and similarly, a randomised controlled 
trial of the LoD approach for the hs-cTnT 
is being planned (LoDED study, personal 
communication Dr Edd Carlton). Both 
trials will give complementary insight into 
the safety and efficacy of this approach.
For the clinician who plans to imple-
ment this strategy prior to the outcomes 
of these randomised controlled trials, 
there are some important considerations. 
Patients who present early after onset of 
symptoms are challenging to recruit and 
therefore under-represented in all observa-
tional cohort studies. It is therefore recom-
mended that serial testing is performed in 
all who present early after onset of symp-
toms. Similarly, any patient with myocar-
dial ischaemia on the ECG should not be 
considered for early rule out and should 
undergo serial troponin testing. Of utmost 
importance is an awareness of the assay in 
use at your institution, the normal refer-
ence range and the appropriate diagnostic 
and risk stratification thresholds which 
are not equivalent. Where low concen-
trations are reported, it is important to 
ensure appropriate standards for clinical 
reporting can be met and maintained 
under routine working conditions. As 
noted by NICE, implementation of the 
proposed early rule-out strategy should 
include clinical audit, with attention paid 
to the time taken to rule out the diagnosis 
and on the clinical outcomes of patients 
with suspected acute coronary syndrome.
Clinicians should be confident that 
newer approaches using low concentra-
tions of cardiac troponin are a magnitude 
safer than prior strategies using the 99th 
centile alone at presentation and 3 hours as 
recommended in the European Society of 
Cardiology guidelines.8 Clinicians should 
be prepared to restructure the assessment 
of patients with suspected acute coronary 
syndrome in their institution to harness 
the potential of high-sensitivity cardiac 
troponin testing, and to improve the effi-
ciency and safety of healthcare delivery.
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